Neuromod Devices Ltd.

Neuromod Devices occupies a specialized position in medical devices and neuroscience, focused almost exclusively on tinnitus rather than competing across broad hearing-care or general neuromodulation categories. Its core differentiation is LENIRE®, a non-invasive bimodal neuromodulation device combining auditory stimulation with tongue stimulation. The company also describes LENIRE as the first FDA-approved device of its type for tinnitus, giving it a distinct regulatory and clinical positioning. However, Neuromod’s market profile is differentiated by the combination of a commercial product, dedicated clinical programs such as TENT-A1 and TENT-A2, provider training, and patient-support services. Regulatory expansion into Canada in 2026 and planned availability in Australia suggest a broader international commercial footprint. Its evidence base includes peer-reviewed real-world studies and recognition from Tinnitus UK, while its risks include dependence on a focused indication, the need to educate hearing-care providers, and the operational complexity of scaling access across different healthcare systems. Funding from Fountain Healthcare Partners, Panakès Partners, and the European Investment Bank has supported this transition from clinical development toward global commercialization.

Neuromod Devices has progressed from early-stage development into a larger, internationally commercializing medical-device company. Founded in 2010, it raised seed funding in 2011, followed by a 2015 Series A, a 2019 capital raise recorded as Series A, and a 2020 Series B of approximately $12.4 million. The 2023 financing expanded materially through a $16.6 million Series B and a separate $16.6 million debt-financing round, followed by a further $10.9 million Series B financing on Mar 11, 2025. Cumulative funding is approximately $73.2 million. Operationally, the company planned to recruit 40 employees across Europe in 2020 and is now represented in an estimated 51-100 employee range. Product and market inflection points include LENIRE’s FDA approval, publication of real-world clinical evidence, the 2025 launch of a tinnitus education masterclass, and the 2026 Canadian rollout across 21 clinics. The February 2026 announcement of 25 new jobs and the October 2026 appointment of Joe Ghiz as Chief Commercial Officer indicate that growth is increasingly tied to market access, provider adoption, and international sales execution rather than only research and regulatory milestones.